How Mindray’s BC-6800Plus Pushes High-Volume Hematology into Automated Territory

Mindray BC-6800Plus 5-Part Differential Hematology Analyzer

The BC-6800Plus is a 5-part differential hematology analyzer rated at 200 tests per hour, with a 100-sample onboard capacity that keeps workflows continuous. It is built around SF Cube technology and fluorescent staining, which together improve the differentiation of white blood cells, reticulocytes, and platelets without additional reagents.

The system detects nucleated red blood cells and basophils as part of its standard CBC differential, removing the need for separate manual checks. It also automatically calculates the neutrophil-to-lymphocyte ratio, a marker increasingly used in inflammation and prognosis tracking.

Automation features such as reflex testing and automatic rerun reduce technician intervention, which in high-throughput settings translates directly into lower error rates and faster turnaround times. For labs where staffing is tight, that matters.

Mindray’s position in this segment is instructive. The company has built a hematology portfolio that competes directly with Siemens, Sysmex, and Beckman Coulter on performance, while offering pricing that aligns with China’s hospital procurement budgets. The BC-6800Plus is not an outlier — it fits a pattern of Chinese diagnostics firms scaling up precision while keeping operational costs undercutting legacy players.

The real competition here is not specs. It is the ability to deliver dependable high-throughput systems into cost-sensitive, volume-driven environments. That is where Mindray’s manufacturing scale and supply chain integration give it an edge that is hard to replicate.

For any lab manager comparing total cost of ownership between the BC-6800Plus and a Tier-1 alternative, the question is no longer whether Chinese analyzers can match performance. It is whether the premium for the established brand still makes sense.

Why it matters:
The BC-6800Plus is a concrete example of how China’s diagnostic equipment manufacturers are moving beyond price competition into technical parity. For hospital laboratories managing high test volumes, it represents a viable alternative to the incumbent players — with lower capital expenditure and comparable throughput.

View Product →